the mechanism of action of navtemadlin and its role in mf
Published 1 year ago • 83 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
11:55
trial of vadastuximab talirine combined with 7 3 induction therapy for newly diagnosed aml patients
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:06
mechanism of action of mitapivat and its potential in the treatment of scd
-
9:04
how are et, pv and myelofibrosis monitored?
-
4:41:40
chem7 training russia, moscow
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:07
advancements in combination strategies with jak inhibitors for myelofibrosis
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:07
an update on astral-3: guadecitabine vs treatment of choice in adults with previously treated mds
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
0:47
tamibarotene combined with azacitidine and venetoclax to treat aml and mds with rara abnormalities
-
1:02
dreamm-3: safety of belantamab mafodotin versus pom/dex in patients with r/r myeloma
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
0:42
haploidentical transplant in argentina
-
1:59
microbiota and gvhd: a double-edged sword
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
4:48
an insight into the management of cytopenias in mf
-
2:16
determining when to switch from hydroxyurea to interferon-based therapy in patients with pv
-
1:56
investigating linvoseltamab monotherapy in smm: the linker-smm1 trial
-
1:17
phase ii study of tosedostat in mds